肺分配评分对肺动脉高压患者仍不公平,即使经过2015年修订
该研究基于器官共享联合网络移植登记数据,比较2015年肺分配评分(LAS)修订前后四个诊断类别患者的等待名单死亡与移植竞争风险。结果显示,修订后肺动脉高压(PAH)患者匹配时LAS增加14.2分,但仍具有最高死亡风险和最低移植率。结论认为2015年修订改善了PAH患者移植可及性并降低等待名单死亡风险,但差异仍然存在。
要点
- 2015年LAS修订后PAH患者匹配时LAS增加14.2分,为各诊断类别中增幅最大。
- 修订后PAH患者等待名单死亡风险仍最高,与间质性肺疾病患者相似。
- 修订后PAH患者移植率仍最低,与慢阻肺患者相似。
核心结论
- 2015年LAS修订改善了PAH患者移植可及性并降低等待名单死亡风险,但未达预期目标。
- PAH患者在等待名单死亡风险和移植可能性方面仍存在显著差异。
研究设计与样本
- 使用标准移植分析与研究文件,比较2015年LAS修订前后两个时期。
- 登记患者按LAS诊断类别分为:A组慢阻肺、B组肺动脉高压、C组囊性纤维化、D组间质性肺疾病。
- 采用竞争风险回归评估等待名单死亡和移植两个互斥竞争风险,并绘制累积发生率图。
主要发现
- 2015年LAS修订后,PAH登记患者器官匹配时LAS增加14.2分,为各诊断类别中增幅最大(其他类别变化为-0.9至+2.8分)。
- 修订前,PAH登记患者死亡风险最高且移植可能性最低。
- 修订后,PAH登记患者死亡风险仍最高,与间质性肺疾病患者相似;移植率仍最低,与慢阻肺患者相似。
临床怎么用
- 呼吸科智能体应知悉:现行LAS对PAH患者仍存在分配不公平,等待名单死亡风险高且移植率低。
- 对PAH患者进行移植评估和等待名单管理时,需关注其持续存在的移植劣势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: The lung allocation score (LAS) was revised in 2015 to improve waiting list mortality and rate of transplant for patients with pulmonary arterial hypertension (PAH). Objectives: We sought to determine if the 2015 revision achieved its intended goals. Methods: Using the Standard Transplant Analysis and Research file, we assessed the impact of the 2015 LAS revision by comparing the pre- and postrevision eras. Registrants were divided into the LAS diagnostic categories: group A-chronic obstructive pulmonary disease; group B-pulmonary arterial hypertension; group C-cystic fibrosis; and group D-interstitial lung disease. Competing risk regressions were used to assess the two mutually exclusive competing risks of waiting list death and transplant. Cumulative incidence plots were created to visually inspect risks. Measurements and Main Results: The LAS at organ matching increased by 14.2 points for registrants with PAH after the 2015 LAS revision, the greatest increase among diagnostic categories (other LAS categories: Δ, -0.9 to +2.8 points). Before the revision, registrants with PAH had the highest risk of death and lowest likelihood of transplant. After the 2015 revision, registrants with PAH still had the highest risk of death, now similar to those with interstitial lung disease, and the lowest rate of transplant, now similar to those with chronic obstructive pulmonary disease. Conclusions: Although the 2015 LAS revision improved access to transplant and reduced the risk of waitlist death for patients with PAH, it did not go far enough. Significant differences in waitlist mortality and likelihood of transplant persist.
引用
- Kolaitis NA, Chen H, Calabrese DR, et al. The Lung Allocation Score Remains Inequitable for Patients with Pulmonary Arterial Hypertension, Even after the 2015 Revision. Am J Respir Crit Care Med. 2023. PMID: 36094471. doi:10.1164/rccm.202201-0217OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。